Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, discusses what myelofibrosis (MF) research she is watching at the 65th American Society of Hematology Annual Meeting & Exposition.
Venugopal discussed the combination of pelabresib with ruxolitinib in patients with MF. “This is the first combination to be tested, and the phase III data has already been very encouraging, especially with the doubling of the splenic volume reduction rate,” she said.
According to Dr. Venugopal, the splenic volume reduction rate increased from around 30% with ruxolitinib monotherapy to 60% with the combination. The study also saw an encouraging trend for total symptom score improvement with the combination.
“This is a big win for the field, and I’m so looking forward to the details of the data,” Dr. Venugopal concluded.